10X GENOMICS, INC. JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - 10X GENOMICS INC
Financial Performance:
- Revenue & Growth: Single-cell consumables revenue grew mid-single digits sequentially in Q3, defying earlier expectations of a slowdown due to the new Terra platform launch; overall consumable growth remains robust.
- Profitability & Cash Flow: The company generated approximately $100 million in free cash flow over the last 12 months, indicating a strong P&L and operational efficiency.
- Instrument Sales: Aimed to sell 50 Terra instruments by year-end, a target management views as ambitious but confident, with plans to ramp production to 50 units per quarter by Q1.
- Pricing Dynamics: Facing short-term headwinds in average reaction pricing due to the strategic shift to the lower-cost Apex platform, which drives volume but temporarily compresses top-line growth per unit; equilibrium expected within a few quarters.
- Deferred Revenue: Significant backlog exists for Terra instrument deployments, constrained by manufacturing and field service capacity rather than demand.
Guidance and Future Outlook:
- Short-Term: Expect sequential growth to slow in Q4 as Terra placements begin cannibalizing existing Xenium orders, though a cliff-like drop is not anticipated.
- Long-Term Goals: Anticipate Terra to become the primary "workhorse" for large-scale spatial biology and foundation model training, potentially outpacing single-cell platforms (Chromium/Perturb-seq) in future high-volume experiments.
- Product Scalability: Aiming to optimize field service and installation capacity to ensure customer success and immediate consumables pull-through once instruments are installed.
- Market Expansion: Predicts significant growth driven by AI integration, translational oncology research, and the need for comprehensive multi-target diagnostics for new therapeutic modalities (ADCs, bispecifics).
Business Segments and Product Lines:
- Terra (Spatial): The primary growth driver with "exceeding" customer enthusiasm; initial orders show a diverse mix including customers new to spatial biology, not just existing Xenium users.
- Xenium: Continues to show resilience with mid-single-digit sequential growth in consumables; viewed as the most prominent and rapidly growing spatial platform in the absence of direct Terra cannibalization.
- Single-Cell (Chromium/ScRNA-seq): Double-digit reaction growth observed in Flex and Apex kits; Apex strategy focuses on lower price-per-reaction and higher scalability to drive volume.
- Catalyst Research Services (CRS): Experiencing dramatic demand with over 100 customers signed up; serving as a leading indicator for instrument conversion, with a diverse customer base including academia, biopharma, and even non-traditional sectors like Procter & Gamble.
- Clinical Initiatives: Establishing a CLIA lab and developing Laboratory Developed Tests (LDTs) to generate clinical evidence for spatial biomarkers, targeting integration with pathology workflows.
Market and Competitive Landscape:
- Competitive Moat: Management asserts a multiple-generation technology lead over competitors, citing the innovative depth of the Terra platform and the convergence of genomics and pathology workflows.
- Market Trends: AI is a central catalyst, with Terra positioned as the ideal data generation engine for spatial foundation models; demand is shifting toward massive-scale experiments (billions of cells) requiring high-throughput spatial data.
- Consolidation: Noted industry consolidation (NanoString, Fluent) strengthens the position of remaining leaders; Terra offers a standardized, workflow-integrated solution in a fragmented market.
- Clinical Demand: Identified a "huge unmet need" in oncology for multiplex spatial diagnostics to guide the selection of new therapies, a use case where traditional IHC is insufficient.
Risks and Challenges:
- Supply Chain & Deployment: Rate-limiting factors include manufacturing capacity for Terra instruments and the availability of field service engineers to install and validate units; site readiness and shipping issues require active management.
- Product Cannibalization: Anticipated pressure on existing Xenium spatial business and consumables from the introduction of Terra, though early data suggests the transition is smoother than feared.
- Macro Environment: Academic and government funding remains under pressure, though the company notes the macro environment is currently trending in its favor due to AI investment and biopharma activity.
- Pricing Pressure: The transition to the Apex platform involves a temporary tension between driving volume and maintaining average reaction pricing.
Management Commentary and Tone:
- Confidence: Management tone is highly confident and optimistic, describing the Terra launch as a "fun" and "exhilarating" story with customer enthusiasm exceeding internal expectations.
- Strategic Focus: Emphasis on "optimizing for customer success" and ensuring rapid instrument deployment to validate the platform and drive consumable recurring revenue.
- Innovation: Stressed that Terra is "perfectly built" for the AI era, positioning it as a fundamental shift in how biology is measured at scale.
- M&A Stance: Prioritizing fundamental business health and cash generation; open to inorganic growth opportunities only if they present a clear strategic rationale.
Analyst Questions and Answers:
- Customer Base Evolution: Clarified that initial Terra orders include a significant portion of customers new to spatial biology, not just existing Xenium owners, broadening the total addressable market.
- Pull-Through Framework: Reiterated it is too early for specific granular pull-through numbers due to low initial order volume; focus is on prioritizing funded customers to ensure immediate consumables usage.
- AI & Foundation Models: Differentiated between Perturb-seq (large-scale but embryonic) and spatial data; predicted spatial data from Terra will become the foundation for future large-scale biological models.
- Clinical Pathway: Detailed the strategy to build clinical cohorts and a CLIA lab to prove the correlation between spatial biomarkers and clinical outcomes, addressing the lack of standardization in the current market.
- Workflows: Highlighted Terra's advantage in utilizing standard off-the-shelf slides and H&E workflows, reducing friction for pathologists compared to previous complex genomics tools.
Other Key Points:
- Translational Research: A major use case identified is predicting response to therapy and understanding mechanisms of resistance in oncology using new therapeutic modalities.
- Service Trend: Noted a secular trend toward services where customers prefer buying data/insights rather than capital equipment, validating the expansion of CRS.
- Technology Integration: The convergence of AI inference capabilities with spatial data generation is seen as the key to condensing complex molecular data into actionable clinical decisions.
- Instrument Demand: The internal competition between shipping instruments to customers versus using them for internal Catalyst projects was noted as the "most contentious issue" in the company due to high demand.
- Company
- 10X GENOMICS INC
- Keywords
- 10X GENOMICS INC